Abivax is mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer.

As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.


Kinam Hong

Kinam joined Sofinnova Partners in January 2017. Kinam co-managed the Exane Equinox fund, a global healthcare fund with a focus on later-stage, public biotechnology companies. Kinam invested in global life sciences companies developing innovative medicines with the potential to address areas of lar...